William Rhoda Joins SeaSpine as General Manager of Process Innovation and Development
CARLSBAD, Calif., Dec. 08, 2016 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that William Rhoda has joined the Company as General Manager of Process Innovation and Development.
In this newly created position, Mr. Rhoda will establish and lead a small, focused office in eastern Pennsylvania that will provide additional product development and process improvement resources and bring even more focus to surgeon and patient needs. This office will also serve as a local training and education site for surgeons and distributors in the Eastern United States. Mr. Rhoda will report directly to Keith Valentine, President and Chief Executive Officer.
Mr. Rhoda has more than 20 years of experience in the spinal implant market. He started his career in orthopedics with Synthes Spine and later became a founding member of Globus Medical, where he served as the Vice President of Product Development. While at Globus, he conceived and implemented a rapid product development process that dramatically shortened the time from concept to market introduction of new products.
“SeaSpine is a dynamic organization that has dramatically improved its product development process through both quality and output during the past year,” said Mr. Rhoda. “I am excited to join the team and leverage my experience to further reduce the time to market as we continue to drive innovation and put SeaSpine firmly on the map of innovators in the spine market.”
“I am excited to welcome Bill to our leadership team and look forward to his contributions to drive faster innovation at SeaSpine,” said Keith Valentine. “I am confident that he will be instrumental in adding energy and responsiveness to our engineering effort and keeping us laser-focused on the needs of the surgeon and our sales team.”
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal hardware portfolio consists of an extensive line of products to facilitate spinal fusion in minimally invasive surgery (MIS), complex spine, deformity and degenerative procedures. Expertise in both orthobiologic sciences and spinal fusion hardware product development helps SeaSpine to offer its surgeon customers a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in over 30 countries worldwide.
SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: Mr. Rhoda’s ability to shorten time-to-market, drive faster innovation and position SeaSpine as an innovator in the spine market. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: Mr. Rhoda’s ability to transition in a timely manner, if at all, and to integrate into SeaSpine’s existing infrastructure, including his ability to collaborate successfully with SeaSpine’s existing product development team; Mr. Rhoda’s ability to conceive and implement a rapid product development process at SeaSpine and his ability to shorten the time from concept to market introduction of new products; surgeons’ willingness to adopt new products resulting from such process, including as a result of failure to demonstrate adequate safety or efficacy, whether as a result of rapid development or otherwise; unexpected expense associated with the new Pennsylvania office; and other risks and uncertainties more fully described in our news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.